Joint health, balance, and quality of life in adults with hemophilia A

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project will measure joint status, postural balance, fall history, and health-related quality of life in adults with severe hemophilia A. Eligible participants (age ≥18) with a Hemophilia Joint Health Score (HJHS) single-joint score ≥3 in the knee or ankle will undergo clinical joint exams, standardized balance tests, and validated QoL questionnaires at Van Yuzuncu Yil University. People who use walking aids or who have neurological/psychiatric disorders, chronic inflammatory disease, regular use of medications that affect balance, or recent major lower-extremity surgery are excluded. The study describes associations among arthropathy severity, balance impairment, and daily functioning rather than testing a medical treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of severe hemophilia A
* Age ≥18 years
* A minimum single-joint score of 3 points for the knee or ankle according to the Hemophilia Joint Health Score (HJHS)

Exclusion Criteria:

* Use of walking aids (e.g., crutches)
* Presence of neurological or psychiatric disorders, chronic inflammatory disease, -Regular use of medications that could affect balance,
* History of major lower extremity surgery within the previous six months.

Where it's running

• Van Yuzuncu Yil University
  Van, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Ayse Merve Tat, Assistant Professor
• Email: aysemervetat@yyu.edu.tr
• Phone: +905052431112

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First‑in‑human test of ARD001 in healthy adults and people with hemophilia A

  This study tests ARD001 to see if it is safe and tolerable in healthy adults and in people with hemophilia A, using a single dose (Phase 1) and potentially repeated doses (Phase 2) if results look good.

  Recruiting Phase 1/2 Arditus Pte Ltd · Singapore · NCT07787091

• Hemophilia A: comparing long-acting FVIII replacement vs non-FVIII therapy in kids

  This study tests whether children with moderate to severe Hemophilia A on long-acting FVIII or non-FVIII therapies form clots differently and develop small joint bleeds or early joint changes.

  Recruiting University of Texas Southwestern Medical Center · Dallas, Texas · NCT07692217

• SR604: a new treatment tested in adults with Hemophilia A/B or congenital Factor VII deficiency

  This study tests a single and multiple doses of SR604 to see if it is safe and effective for adults with Hemophilia A or B, with or without inhibitors, and for those with congenital Factor VII deficiency.

  Recruiting at 7 sites Phase 1/2 Shanghai RAAS Blood Products Co., Ltd. · Changsha and 8 other locations · NCT07644832

• Bone health in severe hemophilia A: emicizumab vs efanesoctocog alfa

  This study tests whether bone density and bone health markers differ in adults with severe hemophilia A who use emicizumab versus efanesoctocog alfa for prophylaxis.

  Recruiting Arkansas Children's Hospital Research Institute · Little Rock, Arkansas · NCT07582276

• NXT007 versus emicizumab to prevent bleeds in people with Hemophilia A

  This will test whether NXT007 prevents bleeding better than emicizumab in people aged 12 and older with Hemophilia A, including those with or without factor VIII inhibitors.

  Recruiting at 63 sites Phase 3 Hoffmann-La Roche · Orange, California and 62 other locations · NCT07416604

• Comparing NXT007 injections with Factor VIII prophylaxis for people with moderate-to-severe hemophilia A

  This will see if regular NXT007 injections prevent bleeds better than standard Factor VIII prophylaxis in people aged 12 and older with moderate-to-severe hemophilia A who do not have FVIII inhibitors.

  Recruiting at 36 sites Phase 3 Hoffmann-La Roche · Aurora, Colorado and 35 other locations · NCT07416526

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.